Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
acute, affiliated, allogeneic, amalgamation, antagonist, Appeal, augmenting, backlog, bioresearch, black, Brun, caught, celiac, Chen, closure, complaint, Computershare, dampened, deficiency, discolored, Doberstein, donor, EMA, enthusiasm, eosinophilic, excise, faster, fatal, Fortune, GI, GvHD, heavy, hematopoietic, HSCT, Hubert, inconvenient, inflationary, inherited, Instruction, liver, main, membrane, mislabeling, mouth, NK, nonrenewal, nonscaring, nonscarring, onset, oustanding, patchy, pigmentation, preapproval, PTAB, remeasurement, restart, retention, routine, scalp, Scott, Silvergate, slot, Stephen, SVB, swept, tender, tighter, tornado, tract, transplant, transplantation, transplanted, unusual, vigorously, void, worsening, wrong
Removed:
accelerated, allocated, amortization, anniversary, certified, combined, comprised, converted, deducting, depreciated, emerging, enterprise, exemption, facilitate, generic, golden, HHS, holding, impede, incorporate, insolvency, investing, Jumpstart, loan, modify, objective, package, parachute, pharmacy, predominant, propose, protective, ratio, recommend, reimburse, replacement, retirement, revised, sheet, split, Telluride, therapy, treated, unaudited, uncured, underwriting, utilization, view
Filing tables
Filing exhibits
FBRX similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Forte Biosciences, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: March 31, 2023 |
| By: | /s/ Antony Riley |
|
|
| Antony Riley |
|
|
| Chief Financial Officer |